Milestone Pharmaceuticals enrolls first European patient in Phase 3 trial
Milestone Pharmaceuticals said the first European patient has been enrolled in its ReVeRA-301 Phase 3 trial of etripamil nasal spray for AFib-RVR. The company said enrollment is advancing toward a target of about 150 patients.